Novel antibody boosts responses in newly diagnosed AML
3 Dec 2016
Novel antibody boosts responses in newly diagnosed AML
Vadastuximab talirine in combination for newly diagnosed AML
Remissions following anti-CD22 CAR therapy in children with relapsed ALL
Subgroup analysis of elderly high risk AML patients receiving CPX-351
A new spin on leukaemia therapy
Anti CD22 CAR T cell therapy for relapsed paediatric ALL
CPX-351 after stem cell transplant for elderly patients with AML
Advanced oral cancer in St Petersburg
Advantages of PET CT scanning
Radiotherapy or surgery for oral cavity tumours?
Therapeutic targeting of childhood medulloblastoma
Improving the evidence base for symptom control